TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science ...
TriLink BioTechnologies, a Maravai LifeSciences company and provider of life science reagents and services, has partnered ...
TriLink BioTechnologies, a Maravai LifeSciences company (MRVI), has partnered with, Avantor (AVTR) to expand availability of its innovative ...
The proposed guidance aims to provide a framework for the approval of personalised mRNA-based cancer vaccines.
Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech ...
KBR announced today its participation in upcoming February 2025 investor conferences. TD Cowen 46th Annual Aerospace and ...
The Board declared a quarterly dividend of $0.125 per share, payable on April 3, 2025 to shareholders of record on March 12, 2025.
The acquisition will expand Maravai and TriLink BioTechnologies' ability to enable customers to develop next-generation mRNA and CRISPR nucleic acid-based therapies. “Molecular Assemblies is the ...
Maravai LifeSciences (MRVI) announced its acquisition of intellectual property and relevant assets from Molecular Assemblies, or MAI. The ...
Marvai LifeSciences has acquired assets and intellectual property from Molecular Assemblies at undisclosed terms. Marvai, a San Diego company, said Tuesday that the acquisition would expand the ...
This acquisition is set to enhance the capabilities of Maravai's subsidiary, TriLink BioTechnologies, particularly in the field of mRNA and CRISPR nucleic acid-based therapies manufacturing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback